Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Curr Drug Deliv ; 15(8): 1204-1215, 2018.
Article in English | MEDLINE | ID: mdl-29866006

ABSTRACT

OBJECTIVE: The incredibly serious problem of Hepatitis B is virus-related chronic liver disease. The conventional preventive treatment of Hepatitis B requires booster dose, which requires repeated administration of the vaccine to the subject. Thus, there is a need to develop a formulation which can eliminate the need of frequent dosing and enhance patient's acquiescence. To prepare single dose nanovaccine of HBsAg by utilizing central composite design for optimization and interaction of independent variables effects on measured response. METHODS: Nanovaccines were characterized for particle size, morphology, integrity, internalization, proliferation response and haemocompatibility. Nanoparticles at single and multiple doses were compared with booster dose of alum-HBsAg vaccine and measure the immunological marker and cytokine (interleukin-2 and interferon-Y) levels by ELISA techniques in BALB/c mice. RESULTS: The designed nanoparticles were found to have nanometric size, high entrapment efficiency and retained antigen integrity. Nanoparticles showed maximum proliferation and efficiently internalized by lymph and spleen cell without eliciting significant toxicity and haemocampatible. CONCLUSION: The comparable data of anti-HBsAg titre between nanovaccine and alum adsorbed HBsAg demonstrated that single dose of nanoparticles is sufficient for production of immunoglobulin plus cytokine levels, maintain immunogenicity at longer period of time and eliminate the booster dose. Nanovaccines trigger immune responses and showing adjuvant properties.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Alum Compounds/administration & dosage , Hepatitis B Antigens/administration & dosage , Immunization/methods , Lactic Acid/administration & dosage , Nanoparticles/administration & dosage , Polyglycolic Acid/administration & dosage , Adjuvants, Immunologic/chemistry , Alum Compounds/chemistry , Animals , Cell Proliferation/drug effects , Drug Compounding , Drug Liberation , Erythrocytes/drug effects , Female , Hemolysis/drug effects , Hepatitis B Antigens/chemistry , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Interferon-gamma/immunology , Interleukin-2/immunology , Lactic Acid/chemistry , Lymphocytes/drug effects , Mice, Inbred BALB C , Nanoparticles/chemistry , Platelet Aggregation/drug effects , Polyglycolic Acid/chemistry , Polylactic Acid-Polyglycolic Acid Copolymer
2.
J Immunol Res ; 2014: 764234, 2014.
Article in English | MEDLINE | ID: mdl-25759834

ABSTRACT

BACKGROUND: The aim of this study was to establish a hepatitis B virus (HBV) vaccination protocol among orthotopic liver transplantation (OLT) recipients under the coverage of a low-dose hepatitis B immunoglobulin (HBIG) combined with an antiviral agent prophylaxis protocol. METHOD: Two hundred OLT recipients were included in this study. The vaccine was injected at months 0, 1, 2, and 6. Low-dose HBIG combined with antiviral agent prophylaxis protocol was continued before reestablishment of active immunity against HBV in order to maintain a steady anti-HBs titer. RESULTS: Active immunity against HBV was reestablished in 50 patients, for an overall response rate of 25%. Of the 50 patients, 24 discontinued HBIG without any HBV graft reinfection during a follow-up period of 26.13 ± 7.05 months. 21 patients discontinued both HBIG and antiviral agents during a follow-up period of 39.86 ± 15.47 months, and 4 patients among them appeared to be HBsAg positive. There was no recipient death or graft loss because of HBV reinfection. CONCLUSIONS: Vaccination preventing HBV reinfection for OLT recipients is feasible. The strategy withdrawal of HBIG with induction of active immunity against hepatitis B is reasonable for long-term survivors of OLT; however, discontinuation nucleoside analogues should be cautious.


Subject(s)
Antiviral Agents/administration & dosage , End Stage Liver Disease/immunology , Hepatitis B Antigens/administration & dosage , Hepatitis B Vaccines , Hepatitis B virus/immunology , Hepatitis B/immunology , Liver Transplantation , Adult , Aged , End Stage Liver Disease/complications , End Stage Liver Disease/therapy , Feasibility Studies , Female , Follow-Up Studies , Graft Survival , Hepatitis B/complications , Hepatitis B/therapy , Hepatitis B Antibodies/blood , Humans , Immunity/drug effects , Male , Middle Aged , Prospective Studies , Transplants/immunology , Transplants/virology , Virus Activation/drug effects
3.
Int J Pharm ; 408(1-2): 50-7, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21291968

ABSTRACT

Presently available marketed alum adsorbed hepatitis B vaccine used for prophylactic immunization, can effectively elicit humoral immunity but is poor inducer of cell-mediated immunity (CMI). Besides, conventional alum-adjuvant vaccines require multiple injections to achieve long-lasting protective immune responses. Therefore, as a result of insufficient immunization, infections are still the leading killer among diseases. The present investigation was therefore, aimed at developing "single-shot" HBsAg adsorbed microspheres of poly (DL)-lactide-co-glycolide (PLGA) (L/G 50:50 and 75:25) and their capability to stimulate the cell mediated immune response against hepatitis B surface antigen. These microspheres were characterized in vitro for their size, shape polydispersity index, percentage HBsAg adsorption efficiency and in vitro release profile. The immune-stimulating activities were also studied following subcutaneous injection of HBsAg adsorbed PLGA microspheres (single-dose on day 0) and compared with alum adsorbed vaccines (two-doses on 0 and 28 days) in Balb/c mice. Specific cell-mediated immune responses such as lymphocyte transformation assay (stimulation-index) including release of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and nitric-oxide were determined. Cellular responses in case of alum adsorb HBsAg vaccine was very low. These studies demonstrate the potential of cationic polymeric microspheres based vaccine in stimulating cell mediated immune response along with humoral response against hepatitis B.


Subject(s)
Drug Carriers/chemistry , Hepatitis B Antigens/immunology , Hepatitis B Vaccines/administration & dosage , Immunity, Cellular/immunology , Immunity, Humoral/immunology , Lactic Acid/chemistry , Polyglycolic Acid/chemistry , Animals , Cations , Drug Stability , Electrophoresis, Polyacrylamide Gel , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/chemistry , Injections, Subcutaneous , Interferon-gamma/blood , Interferon-gamma/immunology , Interleukin-2/blood , Interleukin-2/immunology , Mice , Mice, Inbred BALB C , Microscopy, Electron, Scanning , Microspheres , Molecular Weight , Nitric Oxide/blood , Nitric Oxide/immunology , Particle Size , Polylactic Acid-Polyglycolic Acid Copolymer , Recombinant Proteins/administration & dosage , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Surface Properties , Technology, Pharmaceutical
4.
J Control Release ; 147(2): 211-7, 2010 Oct 15.
Article in English | MEDLINE | ID: mdl-20620183

ABSTRACT

An alternative vaccine delivery system for needle injections is the Bioneedle. Hepatitis B surface antigen (HBsAg) was formulated with Bioneedles. Three formulations were used: plain antigen, HBsAg adjuvated with aluminum hydroxide and HBsAg with LPS-derived lpxL1. Bioneedles with HBsAg-lpxL1 were the most stable and the most immunogenic formulations. The conventional liquid alum adjuvated vaccine lost 40% of its antigenicity after 1week at 50°C whereas the HBsAg-lpxL1 Bioneedles showed no significant decrease after 3 weeks at 50°C. In vivo studies revealed that the HBsAg-lpxL1 Bioneedle formulations induced comparable IgG titers as conventional liquid formulations after 2 immunizations, but higher IgG2a titers were found already after 1 immunization. The in vivo and in vitro studies showed that the Bioneedle is an attractive alternative for needle injections of HBsAg vaccines.


Subject(s)
Absorbable Implants , Drug Delivery Systems/instrumentation , Drug Delivery Systems/methods , Hepatitis B Vaccines/administration & dosage , Adjuvants, Immunologic , Animals , Biocompatible Materials/chemistry , Circular Dichroism , Drug Compounding , Enzyme-Linked Immunosorbent Assay , Freeze Drying , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/immunology , Hepatitis B Vaccines/immunology , Immunoglobulin G/blood , Immunoglobulin M/blood , Mice , Mice, Inbred BALB C
5.
AAPS J ; 12(3): 330-7, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20419360

ABSTRACT

Novel nanoparticle-aggregate formulations containing recombinant hepatitis B surface antigen (rHBsAg) were administered to the lungs of guinea pigs and antibodies generated to this antigen evaluated. Preparations of dry powders of: (a) rHBsAg encapsulated within poly(lactic-co-glycolic acid) (PLGA)/polyethylene glycol (PEG) nanoparticles (antigen nanoparticles, AgN(SD)), (b) rHBsAg in a physical mixture with blank PLGA/PEG nanoparticles (antigen nanoparticle admixture (AgNA(SD)), and (c) rHBsAg encapsulated in PLGA/PEG nanoparticles plus free rHBsAg (antigen nanoparticles and free antigen), were generated by spray drying with leucine. Control groups consisted of alum with adsorbed rHBsAg (AlumAg); reconstituted suspensions of spray-dried rHBsAg-loaded PLGA/PEG nanoparticles with leucine; and rHBsAg-loaded PLGA/PEG nanoparticles (AgN). Control preparations were administered by intramuscular injection; AgN was also spray instilled into the lungs. The IgG titers were measured in the serum for 24 weeks after the initial immunization; IgA titers were measured in the bronchio-alveolar lavage fluid. While the highest titer of serum IgG antibody was observed in guinea pigs immunized with AlumAg administered by the IM route, animals immunized with powder formulations via the pulmonary route exhibited high IgA titers. In addition, guinea pigs immunized with AgNA(SD) via the pulmonary route exhibited IgG titers above 1,000 mIU/ml in the serum (IgG titers above 10 mIU/ml is considered protective). Thus, the disadvantages observed with the existing hepatitis B vaccine administered by the parenteral route may be overcome by administering them as novel dry powders to the lungs. In addition, these powders have the advantage of eliciting a high mucosal immune response in the lungs without traditional adjuvants.


Subject(s)
Hepatitis B Antigens/administration & dosage , Nanoparticles , Administration, Inhalation , Animals , Bronchoalveolar Lavage Fluid , Enzyme-Linked Immunosorbent Assay , Guinea Pigs , Hepatitis B Antibodies/biosynthesis , Microscopy, Electron, Scanning
6.
Curr HIV Res ; 6(5): 452-60, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18855656

ABSTRACT

The cell-mediated immune response to HIV-1 is an essential element of the mechanisms for viral replication control. Currently, most of the vaccine candidates in clinical trials were developed to stimulate HIV-1-specific CD8+ cytotoxic (CTL) and CD4+ T helper (Th) lymphocytes. We have been working on a novel approach to develop a vaccine formulation for HIV-1 using a recombinant multiepitopic protein (named CR3), which comprises CTL and Th epitope-rich regions of HIV-1 from several subtype B isolates, co-inoculated with the hepatitis B virus surface (HBsAg) and core (HBcAg) antigens of the hepatitis B virus (HBV) as adjuvant. According to our studies in mice, the nasal-subcutaneous co-administration of this multiantigenic formulation induces a strong Th1-biased specific response against CR3, CD8+ T cells in mice spleen and IFN-gamma-secreting cells in mesenteric lymph nodes. Cross-reactive p24-specific IFN-gamma-secreting cells in spleen were also detected. Moreover, Nef-specific antibodies were elicited in mice sera which might avoid the toxic effects of this antigen. However, a marginal anti-CR3 antibody response was elicited in vaginal mucosa. Additionally, we observed anti-HBsAg and anti-HBcAg cellular and humoral responses. In this regard, our multiantigenic formulation might provide immunity against HBV as an additional benefic considering the high HIV-1-HBV co-infection rate reported worldwide.


Subject(s)
AIDS Vaccines/immunology , Adjuvants, Immunologic/pharmacology , Administration, Intranasal , Antigens, Viral/immunology , HIV-1/immunology , Hepatitis B Antigens/pharmacology , Hepatitis B virus/immunology , Injections, Subcutaneous , AIDS Vaccines/administration & dosage , Adjuvants, Immunologic/administration & dosage , Animals , Antigens, Viral/administration & dosage , CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , Female , HIV Antibodies/analysis , HIV Core Protein p24/immunology , Hepatitis B Antibodies/blood , Hepatitis B Antigens/administration & dosage , Immunity, Mucosal , Interferon-gamma/metabolism , Lymph Nodes/immunology , Mice , Mice, Inbred BALB C , Spleen/immunology , Vagina/immunology , nef Gene Products, Human Immunodeficiency Virus/immunology
7.
Ultramicroscopy ; 108(10): 1168-73, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18554804

ABSTRACT

Hepatitis B is a deadly disease, and is carried by 30% of the world's population. Antibodies are produced through a series of three manual vaccinations during infancy and childhood. However, the current needle vaccination not only induces pain in patients, but also can be inconvenient to administer. This is particularly true for the case of newborn babies. Intranasal vaccination is emerging as an alternative parenteral drug delivery method that facilitates drug delivery without causing pain. Chitosan, which is obtained through the deacetylation of chitin from crustacea, is a cationic polymer that is biodegradable, avirulent, and highly absorptive. In this study, ionic gelation between chitosan and TPP was conducted to synthesize chitosan nanoparticles with sizes of 200-400 nm and a surface potential of 55-60 mV, and which can be used as Hepatitis B vaccine carriers. Then, Hepatitis B antigen protein was impregnated to manufacture chitosan-recombinant gene vaccine protein (RGVP) nanoparticles. AFM, SEM, TEM, and STEM were used to analyze the manufactured nanoparticles, whose function as drug carriers and whose usefulness for intranasal vaccination were confirmed through in vivo tests with SD rats.


Subject(s)
Chitosan/administration & dosage , Drug Delivery Systems , Hepatitis B Antibodies/blood , Hepatitis B Antigens/administration & dosage , Hepatitis B Vaccines/administration & dosage , Hepatitis B/prevention & control , Nanoparticles/administration & dosage , Animals , Chitosan/chemistry , Chitosan/metabolism , Hepatitis B/immunology , Hepatitis B Antigens/chemistry , Hepatitis B Antigens/genetics , Hepatitis B Antigens/immunology , Hepatitis B Vaccines/genetics , Hepatitis B Vaccines/immunology , Male , Microscopy, Atomic Force , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission , Nanoparticles/chemistry , Polyphosphates/administration & dosage , Polyphosphates/chemistry , Rats , Rats, Sprague-Dawley
8.
Rev Inst Med Trop Sao Paulo ; 46(2): 103-7, 2004.
Article in English | MEDLINE | ID: mdl-15141282

ABSTRACT

We evaluated the immunogenicity of three recombinant hepatitis B vaccines, one Brazilian (Butang, Instituto Butantan) and two Korean vaccines (Euvax-B, LG Chemical Ltd. and Hepavax-Gene, Greencross Vaccine Corp.), administered intramuscularly to students aged 17 to 19 years in three 10- micro g doses (corresponding to half the amount of antigen routinely used for adult vaccination) at intervals of one month between the first and second dose, and of four months between the second and third dose. A total of 316 students non-reactive for any serological marker of hepatitis B virus infection were vaccinated: 77 (24.4%) with the Butang vaccine, 71 (22.5%) with Euvax-B, 85 (26.9%) with Hepavax-Gene and, for comparison, 83 (26.2%) with Engerix-B (GlaxoSmithKline), whose efficacy in young adults at the dose used here has been confirmed in previous studies. Similar seroconversion rates (anti-HBs > 10 mIU/mL about one month after application of the third dose) were obtained for the Butang, Euvax-B, Hepavax-Gene and Engerix-B vaccines (96.2%, 98.6%, 96.5% and 97.6%, respectively). The frequency of good responders (anti-HBs > 100 mIU/mL) was also similar among students receiving the four vaccines (85.8%, 91.6%, 89.4% and 89.2%, respectively). The geometric mean titers (GMT) of anti-HBs about one month after the third dose obtained with these vaccines were 727.78 +/- 6.46 mIU/mL, 2009.09 +/- 7.16 mIU/mL, 1729.82 +/- 8.85 mIU/mL and 2070.14 +/- 11.69 mIU/mL, respectively. The GMT of anti-HBs induced by the Euvax-B and Engerix-B vaccines were higher than those obtained with the Butang vaccine (p < 0.05); this difference was not significant when comparing the other vaccines two-by-two. No spontaneous adverse effects attributable to the application of any dose of the four vaccines were reported.


Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Adolescent , Adult , Female , Hepatitis B Antibodies/immunology , Hepatitis B Antigens/administration & dosage , Hepatitis B Vaccines/administration & dosage , Humans , Immunization Schedule , Male , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
9.
J Immunol ; 170(3): 1183-90, 2003 Feb 01.
Article in English | MEDLINE | ID: mdl-12538674

ABSTRACT

We have previously reported several CTL epitopes derived from the hepatitis B viral X Ag (HBx). In this study, we evaluated whether HBx-specific CTLs can be effectively used in adoptive cancer immunotherapy. To validate the possibility, four peptides containing a HLA-A2.1-restricted binding consensus motif were identified from the HBx protein and tested for their ability to activate CTL from PBMCs isolated from chronic carriers of HBV (n = 12). We selected two highly potent epitopes, HBx 52-60 (HLSLRGLFV) and HBx 115-123 (CLFKDWEEL), that are capable of inducing Ag-specific cytotoxic T cells in patient PBMCs. For adoptive immunotherapy using HBx-specific CTLs, we generated CTL clones restricted to the HBx 52-60 or HBx 115-123 peptide using a limiting dilution technique. LC-46, an HBx 52-60-specific clone, is CD62L(-)CD69(+)CD45RO(+)CD45RA(-)CD25(dim) and is stained by IFN-gamma (approximately 92%), IL-2 (30%), and TNF-alpha (56%), but not by IL-5, IL-10, IL-12, or TNF-beta, indicating that the cells are fully activated T cytotoxic 1-type cells. When LC-46 cells were adoptively transferred into xenografted nude mice bearing human hepatomas expressing HLA-A2.1 molecules and intracellular HBx proteins, the tumors were eradicated. Taken together, our data provide solid evidence for the feasibility of adoptive immunotherapy with HBx-sensitized CTLs in hepatitis disease, including hepatocellular carcinoma (HCC).


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , Hepatitis B Antigens/immunology , Hepatitis B virus/immunology , Immunotherapy, Adoptive/methods , Trans-Activators/immunology , Transplantation, Heterologous/immunology , Animals , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/transplantation , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/therapy , Carrier State/immunology , Cell Line , Clone Cells , Cytotoxicity, Immunologic , Epitopes, T-Lymphocyte/administration & dosage , Epitopes, T-Lymphocyte/metabolism , HLA-A2 Antigen/analysis , HLA-A2 Antigen/metabolism , Hepatitis B Antigens/administration & dosage , Hepatitis B, Chronic/immunology , Humans , Immunophenotyping , Mice , Mice, Inbred C57BL , Mice, Nude , Peptide Fragments/immunology , Peptide Fragments/metabolism , Protein Binding/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , T-Lymphocytes, Cytotoxic/transplantation , Trans-Activators/administration & dosage , Tumor Cells, Cultured , Viral Regulatory and Accessory Proteins
10.
Wien Klin Wochenschr ; 114(5-6): 175-80, 2002 Mar 28.
Article in English | MEDLINE | ID: mdl-12238305

ABSTRACT

The currently available recombinant hepatitis B vaccines are safe, efficacious and immunogenic. Nevertheless, a high rate of low- and nonresponsiveness to the current vaccine poses a problem since this group remains susceptible to infection with hepatitis B virus. Efforts are underway to develop new vaccines and strategies to enhance seroprotection rates. One possibility under investigation is the low-dose intradermal administration of vaccine since the immune system is well represented in both the epidermis and the dermis. Despite encouraging results concerning the immunogenicity in previous non-responders, the main difficulty is the technique of administration and unacceptable local adverse effects. Promising data have emerged from clinical trials evaluating the immunogenicity of new recombinant vaccines containing the complete pre-S1 and pre-S2 regions of HbsAg and, more recently, of novel adjuvanted hepatitis B vaccines. Future approaches include DNA vaccination and expression of HbsAg determinants in live recombinant vectors.


Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B Vaccines/administration & dosage , Hepatitis B/prevention & control , Dose-Response Relationship, Drug , Hepatitis B/immunology , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/immunology , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Surface Antigens/adverse effects , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/adverse effects , Hepatitis B Vaccines/immunology , Humans , Immune Tolerance/immunology , Injections, Intradermal , Protein Precursors/administration & dosage , Protein Precursors/adverse effects , Protein Precursors/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/immunology
11.
Intervirology ; 44(2-3): 65-77, 2001.
Article in English | MEDLINE | ID: mdl-11509868

ABSTRACT

The control of hepatitis B by vaccination is arguably one of medicine's greatest achievements in terms of protecting infants and adults at high risk of infection. Paradoxically, however, the existence of a large reservoir of chronically infected individuals will not diminish the risk of infection by those coming into close contact with such persons until universal infant immunisation is practised globally and vaccines are in place to ensure maximum efficacy in those with impaired immune responses, immunity is achieved with fewer doses, and immunisation as an adjunct to the antiviral treatment of chronic carriers is adopted. These imperatives have continued to stimulate research into vaccines based on chemically synthesised short peptides, and those systems best suited for their delivery. This review discusses the potential of synthetic peptide formulations as efficient inducers of both humoral and cellular immune responses against hepatitis B, and reviews recent advances in peptide delivery. Synthetic peptide and delivery systems technologies will, amongst others, be of paramount importance in the global fight for the eradication of hepatitis B in the 21st century.


Subject(s)
Hepatitis B Vaccines/immunology , Hepatitis B/immunology , Vaccines, Subunit/immunology , Hepatitis B/prevention & control , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/chemistry , Hepatitis B Antigens/immunology , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/chemistry , Humans , Peptides/administration & dosage , Peptides/chemical synthesis , Peptides/immunology , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/chemistry
12.
Vaccine ; 19(7-8): 877-85, 2000 Nov 22.
Article in English | MEDLINE | ID: mdl-11115711

ABSTRACT

Long-term protection against hepatitis B (HB) disease is dependent on persistence of a strong immune memory. This paper presents and discusses new knowledge that allows a better understanding of the mechanisms of long-term protection following hepatitis B vaccination. Studies have revealed links between specific lymphoproliferation, the in vivo humoral response and immune memory. The strength of immune memory and of a subsequent secondary immune response can therefore be predicted by the antibody response following primary vaccination. Vaccine antigen dose and structure have been identified as important influences in the primary antibody response and development of immune memory. The data and considerations presented support the use of highly immunogenic HB vaccines in order to provide long-lasting protection against HB disease.


Subject(s)
Hepatitis B Vaccines/immunology , Hepatitis B Vaccines/pharmacology , Hepatitis B/immunology , Hepatitis B/prevention & control , Immunologic Memory , Dose-Response Relationship, Immunologic , Hepatitis B Antibodies/biosynthesis , Hepatitis B Antigens/administration & dosage , Humans , Immunity, Cellular , Lymphocyte Activation
13.
Clin Exp Immunol ; 115(3): 508-14, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10193426

ABSTRACT

The aim of this study was to examine the immunomodulating effects of rhIL-12 on the immune response induced by hepatitis B virus (HBV) antigens in clinical subgroups of patients with HBV infection. Peripheral blood mononuclear cells (PBMC) of 80 patients were stimulated with HBsAg, HBcAg, pre-S1Ag and tetanus toxoid in the absence or presence of IL-12 (0.01, 0.1 and 1 ng/ml). Stimulation by anti-CD3+ anti-CD28 and lipopolysaccharide (LPS) were used as controls. Proliferation and cytokine production were determined by 3H-thymidine uptake and ELISA after 72 h. After stimulation with HBV antigens only, production of tumour necrosis factor-alpha (TNF-alpha) or IL-10 was observed in all patients, while interferon-gamma (IFN-gamma) was detectable in only 27 patients. After costimulation with IL-12 and HBV antigens, however, large amounts of IFN-gamma were found in all patients, while HBV-induced IL-10 production remained mostly unchanged. When clinical subgroups including patients with compensated liver cirrhosis were compared, PBMC from patients with HBeAg+ hepatitis showed the lowest capacity to produce IFN-gamma after HBV antigen-positive IL-12. These data suggest that the ability of IL-12 to enhance IFN-gamma production against HBV antigens is correlated with the presence of HBeAg and is not impaired in patients with advanced liver disease. In addition, IL-12 and IL-10 production by antigen-presenting cells may be a critical factor that determines the efficacy of the immune response against the hepatitis B virus.


Subject(s)
Cytokines/biosynthesis , Hepatitis B virus/immunology , Hepatitis B, Chronic/immunology , Antigen-Presenting Cells/immunology , DNA, Viral/blood , Hepatitis B Antibodies/blood , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/blood , Hepatitis B, Chronic/classification , Hepatitis B, Chronic/virology , Humans , In Vitro Techniques , Inflammation Mediators/metabolism , Interferon-gamma/biosynthesis , Interleukin-10/biosynthesis , Interleukin-12/biosynthesis , Interleukin-12/pharmacology , Leukocytes, Mononuclear/immunology , Lymphocyte Activation , Recombinant Proteins/pharmacology , Tumor Necrosis Factor-alpha/biosynthesis
14.
Rev. méd. Inst. Peru. Segur. Soc ; 3(1): 31-5, ene.-mar. 1994. tab
Article in Spanish | LILACS | ID: lil-157004

ABSTRACT

Se investigó la inmunogenicidad (seroconversión, seroprotección hiperrespuesta y media geométrica) producida por la vacuna recombinante cubana contra la hepatitis viral tipo B en nuestro medio, en un estudio multicentrico nacional, concurrente, aplicando el sistema de 0, 1, 2 meses en 211 trabajadores de la salud, susceptibles, pertenecientes al IPSS. La cuantificación del antiHBs se realizó por el método inmunoenzimático de Organon Tecknics. Se obtuvo un 97 por ciento de seroprotección en solo 75 días de haber iniciado el esquema, observandose una mayor inmunogenicidad en mujeres menores de 40 años. Se recomienda la aplicación de este esquema como parte del programa de control en la Hepatitis viral tipo B por su simetría, corta latencia y grado de protección


Subject(s)
Humans , Male , Female , Vaccines/administration & dosage , Hepatitis B/immunology , Immunization/methods , Hepatitis B Antibodies , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/immunology , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Surface Antigens/immunology , Immunization Schedule , Dose-Response Relationship, Immunologic
15.
J Immunol Methods ; 146(1): 17-23, 1992 Jan 21.
Article in English | MEDLINE | ID: mdl-1735778

ABSTRACT

Serum samples were obtained during follow-up of nine young adults vaccinated over 1 year with cDNA hepatitis B antigen. The absolute amounts of anti-HBs IgG subclass antibodies present in the sera were determined by comparing the optical densities (OD) obtained using an antigen-specific ELISA with those obtained by serial dilutions of known amounts of human IgG1-4. The calibration curves for each IgG subclass were corrected for the corresponding coating efficiency. Our data suggest that HBs antibody responses of vaccinated subjects occur in all IgG subclasses but IgG1 and IgG2 are the major subclasses involved.


Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B Antigens/immunology , Immunoglobulin G/blood , Vaccination , Adult , Antibody Formation , Drug Administration Schedule , Female , Hepatitis B Antigens/administration & dosage , Humans , Male , Radioimmunoassay , Time Factors
16.
Res Microbiol ; 141(7-8): 831-7, 1990.
Article in English | MEDLINE | ID: mdl-2101472

ABSTRACT

The aim of our work is to identify hepatitis B virus antigens that can be stably expressed in attenuated Salmonellae and elicit protective immune responses as live oral route vaccines. As a first carrier system, we expressed T-cell and B-cell epitopes of hepatitis B virus as fusion proteins with the non-toxic subunit B (LT-B) in attenuated Salmonellae. These recombinant Salmonellae elicited anti-LT-B T- and B-cell immune responses and anti-HBV nucleocapsid antigen (HBcAg) T-cell responses when fed to mice. To combine the protective potential and the high immunogenicity of HBc with the induction of virus neutralizing antibodies to HBV surface antigen, we constructed vectors expressing hybrid HBc/pre-S particles in which the pre-S epitopes were surface-exposed. With one of these vectors, stable constitutive high level expression of hybrid HBc/pre-S2 particles was achieved in several attenuated Salmonella strains. When recombinant Salmonellae expressing such hybrid HBc/pre-S2 fusion proteins were fed to mice, the animals developed high titres of anti-HBcAg-specific serum IgG after a single or multiple oral immunizations, depending on the strain used as a carrier. In addition, lower titered antibodies against the pre-S2 antibody-binding sites were elicited. This is the first HBV antigen eliciting high-titered immune responses after a single oral immunization in recombinant Salmonellae. The immunogenicity of periplasmic LT-B and cytoplasmic HBc/pre-S2 shows that surface exposure of a foreign antigen is not a prerequisite for its immunogenicity in live attenuated Salmonellae.


Subject(s)
Hepatitis B Antigens/isolation & purification , Salmonella/immunology , Viral Hepatitis Vaccines/isolation & purification , Administration, Oral , Animals , Hepatitis B Antibodies/biosynthesis , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/genetics , Mice , Mice, Inbred Strains , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Salmonella/genetics , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/genetics , Vaccines, Attenuated/isolation & purification , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/isolation & purification , Viral Hepatitis Vaccines/administration & dosage , Viral Hepatitis Vaccines/genetics
17.
Clin Exp Immunol ; 64(2): 285-94, 1986 May.
Article in English | MEDLINE | ID: mdl-3091300

ABSTRACT

Cell mediated immunity (CMI) to hepatitis B viral antigens was studied in BALB/mice after immunization with purified hepatitis B surface antigen (HBsAg), or core antigen (HBcAg), with adjuvants. The two in vitro assays for cell-mediated immunity (CMI), utilizing lymph node cells, were release of interferon after exposure to antigen, and blast transformation of lymphocytes, and the in vivo assay was ear swelling at 24 h after local injection of antigen. Immunization with HBsAg or HBcAg with adjuvants induced antigen-specific cutaneous reactivity; if no adjuvants were given, immunization with HBcAg, but not HBsAg, induced cutaneous reactivity. CMI could be adoptively transferred by lymph node cells, but for only a limited period after immunization with HbsAg or HBcAg. The ability of lymph node cells from mice immunized with HBV antigens to transfer adoptively CMI correlated well with their production of interferon after challenge with antigen in vitro, but less well with blastogenesis after challenge with antigen in vitro, or with cutaneous reactivity to antigen in the donor mouse. Reliable antigen-specific lymphokine release assays, rather than blast transformation of lymphocytes or cutaneous reactivity after antigen challenge, are required to assess CMI to HBV antigens in the mouse and, by inference, in man.


Subject(s)
Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B/immunology , Adjuvants, Immunologic/pharmacology , Animals , Female , Hepatitis B Antigens/administration & dosage , Hypersensitivity, Delayed , Immunity, Cellular , Immunization, Passive , Interferon-gamma/biosynthesis , Lymphocyte Activation , Mice , Mice, Inbred BALB C
18.
Infect Immun ; 43(3): 1000-5, 1984 Mar.
Article in English | MEDLINE | ID: mdl-6698598

ABSTRACT

Delta agent (delta) was serially passaged to a second and third hepatitis B surface antigen (HBsAg) carrier chimpanzee, using as inoculum the peak delta antigen (delta Ag) serum of an animal previously infected with human serum. The characteristics of serially transmitted delta Ag were similar to those described in first-passage animals. It was consistently detected before the development of anti-delta, in association with a 35- to 37-nm subpopulation of HBsAg particles and a unique low-molecular-weight (5.5 X 10(5)) RNA. RNase susceptibility of the delta-associated RNA and release of delta Ag activity upon treatment of delta-associated particles with detergent revealed that this particle is organized into a virion-like form with the RNA and delta Ag as internal components within a coat of HBsAg. Surface determinants of the delta-associated particle other than HBsAg were not detected by radioimmunoprecipitation experiments, using sera of humans and chimpanzees convalescent from delta hepatitis. The HBsAg-associated particle is the "candidate agent" of delta hepatitis.


Subject(s)
Hepatitis B Antigens/isolation & purification , Hepatitis, Viral, Animal/immunology , Animals , Antigen-Antibody Reactions , Carrier State , Centrifugation, Density Gradient , Chemical Precipitation , Guinea Pigs , Hepatitis B Antibodies/immunology , Hepatitis B Antigens/administration & dosage , Hepatitis B Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B virus/immunology , Hepatitis B virus/ultrastructure , Hepatitis delta Antigens , Hepatitis, Viral, Animal/etiology , Humans , Pan troglodytes , RNA, Viral/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...